Extended-spectrum beta-lactamase production among clinical i | 17535
International Research Journals
Reach Us +44 330 818 7254

International Research Journal of Microbiology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Extended-spectrum beta-lactamase production among clinical isolates of Escherichia coli


Okesola Abiola Olukemi and Fowotade Adeola

The extended-spectrum beta-lactamase (ESBL)-producing organisms are increasing rapidly and becoming a major problem in the area of infectious diseases. This study was carried out to detect and document ESBL production among clinical isolates of Escherichia coli in our institution and to determine their antibiotic susceptibility pattern.Fifty-two clinical isolates of E.coli were identified from various clinical specimens brought to the diagnostic medical microbiology laboratory of University College Hospital, Ibadan, in Nigeria. These were subjected to the double-disc synergy test to detect ESBL production among them. 76.9% of these isolates were found to be ESBL producers. The highest production of ESBL was found among the isolates from wound swabs (40%), followed by urine (30%), sputum (10%), and ear swabs (10%).The activities of imipenem, meropenem, gentamycin, amikacin, and ampicillin/sulbactam against the ESBL producers were 80%, 100%,60%, 50% and 10% respectively.The limitation of this study was that confirmatory tests for ESBL production were not done. Characterization of the beta-lactamase enzymes prevalent in this environment is also of utmost importance . The use of third-generation cephalosporins should also be restricted to control the spread of ESBL producers.

Share this article